Navigation Links
Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Date:9/5/2007

VIENNA, Austria, Sept. 5 /PRNewswire/ -- Four analyses of three-year follow-up data showed that the CYPHER(R) Sirolimus-eluting Coronary Stent may be considered an appropriate alternative to bypass surgery in patients with blockages in two or more coronary arteries (multivessel disease). The analyses were presented this week at the European Society of Cardiology Congress 2007 (ESC Congress 2007).

Three of these analyses sought to assess the long-term impact of the CYPHER(R) Stent when the patient with multivessel disease was also diabetic, the length of the blockage was more than 100 mm or the arterial blockage was located in a junction between a main artery and a side-branch artery, a type of blockage also known as bifurcation. A fourth analysis reported the overall incidence of stent thrombosis in the data set using the Academic Research Consortium (ARC) definitions.

These analyses based their results on data from the Arterial Revascularization Therapy Study I and II (ARTS I and II Studies). The ARTS I Study was conducted in 1997 and compared the results of a bare metal stent to those obtained with bypass surgery. The ARTS II Study included 607 patients from 45 European centers treated with the CYPHER(R) Stent. Investigators compared the findings for these patients to those from the ARTS I Study, which included 605 patients treated with bypass surgery and 600 treated with a bare metal stent.

"These analyses contribute significantly to medical understanding of clinical outcomes for the CYPHER(R) Stent in patients with multivessel disease, who remain one of the most complex patient populations with coronary artery disease to treat," said Principal Investigator Patrick W. Serruys, M.D., Ph.D., from Thoraxcenter, Erasmus Medical Center in The Netherlands, who presented one of the analyses at the congress.

In the subgroup analysis of diabetic patients (367 patients or 20 percent of the total ARTS I and II patient populations), clinical in
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Data Analyses Outline Efficacy and Safety of Mircera for the Treatment of Renal Anemia Associated With Chronic Kidney Disease
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
7. Genetic Analysis Systems Enter the Clinical Mainstream
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... second quarter 2014 financial results before the NASDAQ Global ... same day, Arena will host a conference call and ... Time). The conference call may be ... for international callers. Please specify to the operator that ...
(Date:7/24/2014)... OVERLAND PARK, Kan. , July 24, 2014 ... licensing of two compounds that will be added ... agreement with Australian-based CIMTECH Pty Ltd, a biotechnology ... and PAR 122 have shown promise in bone ... a license to develop the compounds for the ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July ... , Weltweite Exklusivlizenz der Universität ... Entwicklung von Tests auf SF3B1-Mutationen, einschließlich von ... Neuer Test weist Mutationen des SF3B1-Gens nach, ... einen günstigen Krankheitsverlauf vermuten lassen  ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Receiving the herpes zoster vaccine was associated with a ... Kaiser Permanente study of 300,000 people that appears in the ... Association . This retrospective study observed the outcomes ... large, diverse population of men and women ages 60 years ...
... 11, 2011 Celleration, Inc., a privately held medical ... products, today announced the closing of an $8 million ... Company,s existing institutional investors participated in this round in ... a new investor. "The addition of ...
Cached Medicine Technology:Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 2Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 3Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 4
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are ... a younger appearance. The Cherry News company has published ... and women explore the availabilities from U.S. retailers at ... in the posted guide on the Cherry News website ... drawback to some natural ingredient formulas is the high ...
(Date:7/27/2014)... CA (PRWEB) July 27, 2014 Ticket Down ... Tickets at The Forum in Inglewood, California on November 15th. ... and diehard fans can expect to hear songs from this amazing ... of Summer concert in Inglewood, California at The Forum will be ... starting at 10:00 a.m. today local time TicketDown.com. This popular ...
(Date:7/27/2014)... The constant expansion of companies across the globe has ... Additional factors that have increased this demand include the ... communication, learning and development, security and safety, and knowledge ... enterprise video market value has crossed $11.21 billion in ... 2018 with a compound annual growth rate (CAGR) of ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market ... Type (OE & Aftermarket), Filter Type (Oil & Fuel), ... Trends & Forecast to 2018”, defines and segments the ... and forecasting of the global volume and revenue. The ... a revenue of $6.1 billion in 2018, while fuel ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The European Bromine ... with analysis and forecast of revenue. , Bromine market in ... France, Spain, and UK. Germany and France that forms a ... and its derivatives in Europe. , Browse through the ... idea of the in-depth analysis provided Browse through the TOC ...
Breaking Medicine News(10 mins):Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4
... risk factors for heart disease, including blood pressure and ... Association recommended Monday in new guidelines for the prevention ... the panel, observed that heart disease actually begins in ... make large changes in behavior early on. He said ...
... to a new research, a daily dose of a soybean ... "bad", or LDL, cholesterol levels in young men. Functional foods ... essential nutrients. //There has been a trend of adding value ... For example, Benecol Spread is a margarine that contains phytosterol ...
... Researchers say a daily teaspoon of lemon-flavored cod liver ... may help prevent middle ear infections in children. New ... infection,// required fewer antibiotics and had fewer ear infections ... oil, which has vitamins A and D and omega-3 ...
... Hopkins found a new study shows some cancer patients ... from treatment with the drug, interferon.,Past research has suggested ... B-cell non-Hodgkin's lymphoma's. //A patient with both of these ... patient responded causing researchers in Paris to study whether ...
... a new study which suggests hormone suppression therapy ... chances of living free of the disease.Michel Bolla, ... potential benefits of suppressing the male hormone androgen, ... testosterone, among 400 patients in advanced stages// of ...
... to take antibiotics before dental cleaning to reduce the ... drugs do not take them, sometimes because their doctors ... realize that the antibiotics are warranted, according to a ... that they say may increase compliance with the antibiotic ...
Cached Medicine News:Health News:Heart attack risk starts at 20 2Health News:Hormone Therapy applicable for Prostate Cancer 2
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Anatomical implants for the entire hand, in five sizes...
... a brief magnetic pulse to stimulate deep ... in Magnetic Nerve Stimulators. Based upon equipment ... in 1985. A powerful monophasic stimulator for ... best stimulator for Central Motor Conduction Studies, ...
Medicine Products: